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Gallagher & Rosenthal, 2008). When used as indicated, these medica-
tions can be an important component of pain management. However,
their high abuse potential presents concerns regarding their nonmedi-
cal use, which can be defined as ‘use of a prescription opioid that wasKeywords:




Youth drug use1. Introduction
Trend analyses of prescription opioids in the U.S. indicate use, espe-
cially use ofprescription opioids stronger thanmorphine, hasmore than
doubled among adults since the early 1990's (Frenk, Porter, & Paulozzi,
2015). Prescription opioids, like Oxycontin®, are effective pharmaco-
logical treatments for acute and chronic pain (Fitzcharles & Shir, 2009;ogy, Mailman School Of Public





u (C.L. Storr),not prescribed, or taken for the experience or feeling it caused’
(SAMHSA, 2014). In the United States, nonmedical use of prescription
opioids (NMPO) is increasingly recognized as a serious public health
problem among adults (Blanco et al., 2007; Han, Compton, Jones, &
Cai, 2015; Huang et al., 2006). Nonmedical prescription drug use, specif-
ically nonmedical use of prescription opioids, is also a growing problem
in other countries such as Canada (Fischer, Gooch, Goldman, Kurdyak, &
Rehm, 2014; Fischer, Ialomiteanu, Kurdyak, Mann, & Rehm, 2013) and
Australia (Degenhardt et al., 2006; Rintoul, Dobbin, Drummer, &
Ozanne-Smith, 2011).
Repeated NMPO use increases the risk of developing an opioid use
disorder. Studies have shown that adults using prescription opioids as
prescribed by a doctor to treat chronic pain are less likely to develop
DSM-IV dependence (Minozzi, Amato, & Davoli, 2013) compared to
nonmedical opioid users (Compton, Dawson, Goldstein, & Grant,
2013; Huang et al., 2006; Peer et al., 2013; SAMHSA, 2009). Thus, it is
important to detect NMPO use early before clinical problems emerge.
Nearly 80% of 12–21 year olds who reported initiation of heroin use
had previously initiated NMPO between the ages 13–18 (Cerda,
Santaella, Marshall, Kim, & Martins, 2015). In general household popu-
lation samples of past-year NMPO users in the U.S., approximately 7%
and 9% of adolescents met criteria for prescription opioid abuse and
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thepast-yearNMPOusers between ages 18–34met criteria for prescrip-
tion opioid use disorder (Becker, Sullivan, Tetrault, Desai, & Fiellin,
2008).
Given this and the high probability of nonmedical use among adoles-
cents and young adults, the potential development of prescription opi-
oid use disorder secondary to nonmedical use among youth
represents an important and growing public health concern. Still, no
study has investigated time trends, specifically if prescription opioid
use disorder has increased in the past decade among adolescents,
emerging adults and young adults who are nonmedical users of pre-
scription opioids.
Heavy use of prescription opioids can affect neurodevelopment dur-
ing critical periods from in utero through adolescence and into young
adulthood (Chambers, Taylor, & Potenza, 2003; Uebel et al., 2015).
Data from Monitoring the Future (MTF) have shown that late high
school (12th grade) medical PO use is associated with adult onset of
NMPO use (Miech, Johnston, O'Malley, Keyes, & Heard, 2015), while
other MTF research has shown declining NMPO use into young adult-
hood after NMPO use in high school (McCabe, Schulenberg, O'Malley
et al., 2014). Further, opioid use disorders can impact all aspects of ado-
lescents' and young adults' lives, including family, school, and the acqui-
sition of adult roles and responsibilities (Boyd, McCabe, & Teter, 2006;
Wu et al., 2011; Wu, Ringwalt, Mannelli, & Patkar, 2008). Despite re-
search findings that young adulthood is a period of high vulnerability
to drug effects (Hwang et al., 2013), adolescent susceptibility to drug ef-
fects might be even greater due to adolescent physiological and social
transitions (Rudolph, Lambert, Clark, & Kurlakowsky, 2001). Thus, it is
important to examine patterns of prescription opioid use disorder in dif-
ferent developmental periods including adolescence, the transition
from adolescence to adulthood and early adulthood.
In addition, previous studies have shown that NMPOuse is a risk fac-
tor for subsequent heroin use (Becker et al., 2008; Compton, Jones, &
Baldwin, 2016; Fogger & McGuinness, 2015; Jones, 2013; SAMHSA,
2011). This is of particular concern given that, in the U.S., the number
of individuals aged 18–25with past-year heroin dependence has almost
doubled between 2002–2005 and 2009–2011 (SAMHSA, 2012a). Also,
the number of adolescents that are dependent on heroin increased sig-
nificantly by N50% (from 8000 to 13,000) (SAMHSA, 2012a). Previous
research has also found an increased use of heroin among youth that
have initiated using prescription opioids nonmedically early in their ad-
olescence, with a peak period of heroin initiation at age 17–18 (Cerda,
Santaella, Marshall, Kim & Martins, 2015).
Using U.S. nationally representative population-based data (2002 to
2014) on adolescents (12–17 years), emerging adults (18–25 years)
and young adults (26–34 years), we sought to answer the following re-
search questions: 1) Were there significant changes between 2002 and
2014 in past-year prescription opioid use disorder secondary to NMPO
use among those whowere nonmedical PO users? 2)Were there signif-
icant changes between 2002 and 2014 in past-year heroin use among
individuals who were NMPO users? Examining changes in prescription
opioid use disorder secondary to prescription opioid use over time and
heroin use amongNMPO users is important for informing policies relat-
ed to prescription opioid use as well as evidence-based prevention and
treatment strategies (NSDUH, 2016). A closer look at earlier critical de-
velopmental periods— in particular adolescence and young adulthood
—is warranted if we want to curb the increasing morbidity and mortal-
ity associated with NMPO use.
2. Materials and methods
2.1. Sample
Data were derived from the 2002 to 2014 National Survey on Drug
Use and Health (NSDUH) specifically focusing on youth who were
NMPO users: 12–17 years old (N = 15,308), 18–25 years old (N =25,751), and 26–34 years old (N= 5121). The NSDUH is sponsored by
the Substance Abuse and Mental Health administration (SAMHSA)
and is designed to provide annual prevalence estimates of nonmedical
use of legal and illegal drugs in the household population 12 years of
age and older in the United States (SAMHSA, 2012a). The survey em-
ploys a 50 state design with an independentmultistage area probability
sample for each state and the District of Columbia and oversamples
younger age groups (aged 12–25) aswell as African-Americans andHis-
panics. Response rates varied between 81.94 and 91.00% for weighted
screening response rate, and between 71.2 and 79.00%, for weighted in-
terview response rate. Interviews were administered by a trained inter-
viewer using computer-assisted personal interviewing (CAPI). Drug
sections were administered more privately using audio computer-
assisted self-interviewing (ACASI) to increase the level of honest
reporting of illegal drug use and other sensitive behaviors (Morral,
McCaffrey, & Chien, 2003). Participants were offered a $30
incentive.Detailed information about the sampling and surveymethod-
ology of NSDUH can be found elsewhere (SAMHSA, 2012a).
2.2. Measures
2.2.1. Past-year nonmedical use of prescription opioids
The survey includes a stem question that first determines if NMPO
use occurred: “These questions are about prescription pain reliever
use.We are not interested in your use of over-the-counter pain relievers
that can be bought in stores without a doctor's prescription.” Partici-
pants endorsed if they had used any NMPO in the past-year by answer-
ing: “how long has it been since you last used any prescription pain
reliever that was not prescribed for you or that you took only for the ex-
perience or feeling it caused” (SAMHSA, 2012a). To improve the quality
of reporting, participants were given a card with names of prescription
opioids (non-opioid medications are not included). Respondents were
asked a series of follow-ups question on specific drugs included in this
class.
2.2.2. Past-year heroin use
Participants were asked if they had used heroin during the past
12 months. Individuals were classified as past-year heroin users if
they endorsed using heroin at least once during the previous 12months.
2.2.3. Prescription opioid use disorder
Information on past-year prescription opioid abuse and dependence
was obtained from a set of structured questions based on criteria for
substance disorders from the Diagnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition (DSM-IV) (American Psychiatric
Association, 2000). The NSDUH provides a summary variable for pre-
scription opioid use disorder based on whether the respondent en-
dorsed 1 of the 4 abuse questions and/or 3 of the 7 dependence
questions. Probable disorder diagnosis based on these questions has
been found to have good agreement with clinical judgement (Jordan,
Karg, Batts, Epstein, & Wiesen, 2008).
2.2.4. Covariates
The covariates considered for adjustmentwere the respondents' sex,
race/ethnicity (Whites, Blacks, Hispanics, Asians, andOther race/ethnic-
ity), and calendar year of interview (2002–2014).
2.3. Data analyses
Data were analyzed using STATA 13.0 (STATA, 2013). Weights were
included to reflect the complex design of the NSDUH/NHSDA sample.
We used Taylor series linearization estimation methods (Stata ‘svy’
commands) to obtain standard errors for the cross-tabulations Past-
year PO use disorder and past-year heroin use were our two main out-
comes. First, we estimated the yearly increase in the odds ratio of past-
year PO use disorder and heroin use among NMPO users, over time
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demographics (sex, race/ethnicity). Then, separately, we estimated the
yearly prevalence of PO use disorder and heroin use by adjusting
weighted linear regression models. We calculated the yearly trend (p-
value for trend) by including year as a continuous variable in separate
linear regression models.
3. Results
Among past-year NMPO users (aged 12–34 years), the majority of
the respondents were Whites (70.80% vs. Blacks = 9.61%, Hispanics =
14.65%, Asians = 2.05% and other race/ethnic group = 2.89%). There
were slightly more males than females (55.05% vs. 44.95). Overall, the
past-year prevalence of NMPO use significantly decreased from 2002
to 2014 among adolescents (7.51% to 4.82%, p-value for trend b 0.05),
among emerging adults ages 18–25 (11.43% to 7.59%, p-value for
trend b 0.05), and among young adults ages 26–34 (6.18% to 6.08%, p-
value for trend b 0.05). Compared to 2002, the yearly prevalence of
NMPO use in 2014 decreased 37% in adolescents (aOR = 0.63;
95%CI = 0.56–0.71), 34% in emerging adults (aOR = 0.66; 95%CI =
0.60–0.73), and remained unchanged in young adults (aOR = 1.00;
95%CI = 0.81–1.23).
3.1. Prescription opioid use disorder among NMPO users: Changes in past-
year prevalence
Fig. 1 illustrates the prevalence of prescription opioid use disorder
among NMPO users from 2002 to 2014. The prevalence of prescription
opioid use disorder significantly increased among emerging adults
aged 18–25 (11.98% to 15.11%, p-value for trend b 0.05, aOR = 1.37;
95%CI = 1.03–1.81), and likewise from 2002 to 2014 among young
adults aged 26–34 (11.27% to 23.52%, p-value for trend b 0.05, aOR =
2.43; 95%CI = 1.56–3.78). Overall, during the study period, the differ-
ence in prescription opioid use disorder prevalence among NMPO
users from 2002 to 2014 was 1.41% in adolescents, 3.13% in emerging
adults and 12.25% in young adults (Fig. 2). Among adolescents (12–
17 years), the prevalence of prescription opioid use disorder remained
relatively stable during the same period (Appendix A: Supplemental
Table 1). From 2002 to 2010 no significant trends were observed;
from 2011 until 2014, emerging and young adults had a significantly
higher prevalence of prescription opioid use disorder compared to ado-
lescents (17.65%, aOR = 1.62, 95%CI = 1.29–2.05; 17.32%, aOR = 1.66,
95%CI=1.01–2.72; 16.36%, aOR=1.41, 95%CI=1.05–1.90; respective-
ly) (Appendix A: Supplemental Table 1).Fig. 1. Adjusted prevalence of prescription opioid use disorder among past-year
nonmedically prescription opioids users, stratified by age, in the U.S. household
population.3.2. Heroin use among NMPO users: changes in past-year prevalence over
time
Fig. 3 shows past-year heroin use among past-year NMPO users, and
we can see an increasing trend from 2002 to 2014 among emerging
adults (2.11% to 7.35%, p-trend b 0.05) and young adults (1.62% to
12.29%, p-trend b 0.05). There is only a slight and non-significant in-
crease in past-year heroin use among adolescents who were also
NMPO users (1.80% to 2.30%, p-trend = 0.17, see Appendix A: Supple-
mental Table 2). The difference in the prevalence of heroin use among
NMPO users from 2002 to 2014 was 0.5%, 5.24% and 10.67% among ad-
olescents, emerging adults and young adults, respectively (Fig. 4). Over-
all, the prevalence of past-year heroin use amongNMPOusers increased
four-fold in emerging adults (aOR = 4.18; 95%CI = 2.59–6.73) and
nine-fold in young adults (aOR = 9.09; 95%CI = 2.96–27.95). Across
the study period, the increment in past-year heroin use ismore dramat-
ically observed from 2012onwards among emerging and young adults
(see Appendix A: Supplemental Table 2; aOR = 3.57; 95%CI = 2.24–
5.70, and aOR = 3.61; 95%CI = 1.05–12.42, respectively).4. Discussion
Themain findings of this study can be described as follows: 1) there
was an increase in the probability of having a prescription opioid use
disorder in the past year among 18–34 year old NMPO users (compared
to 2002, in 2014 there was a 37% increase in the odds of having a disor-
der for emerging adults and a doubling of the odds among young
adults); 2) there was a four-fold and nine-fold increase over time in
the odds of heroin use among emerging adults and young adults who
were NMPO users, respectively; and 3) there were no significant chang-
es prescription opioid use disorder secondary to NMPO use or heroin
use among adolescent users.
Our study's findings parallel the public health concern on the rise of
prescription opioid and heroin overdoses and mortality (Ballantyne &
Kolodny, 2015; CDC, 2012). To our knowledge, this is the first national
study to analyze the time trends of prescription opioid use disorder
and heroin use amongNMPO users on a yearly basis among adolescents
and emerging and young adults over a twelve-year time period. NMPO
use is a common growing public health problem that is not limited to
the United States; prescription opioid consumption doubled from
2004–2006 to 2010–2011 in the general population in Ontario, Canada
(Fischer et al., 2014). Similarly, Australia's general population experi-
enced a 15-fold increase in NMPO, from 1992 to 2012 (Blanch,
Pearson, & Haber, 2014). Research from different countries push for-
ward a similar conclusion: there are important gaps in knowledge in
prescription opioid use and, more specifically, in NMPO use to compute








12-17 yrs (p = 0.19) 18-25 yrs (p < 0.05) 26-34 yrs (p < 0.05)
%
Fig. 2. Average change in the prevalence of prescription opioid use disorder, from 2002 to
2014, among NMPO users by age groups.
Fig. 3. Adjusted prevalence of heroin use among NMPO users in the U.S. household
population (2002–14).
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after 2008, among theU.S. general population are declining. This finding
is in contrast with increases seen in the general U.S. population before
2007 according to national representative data (SAMHSA, 2008), and
data from the Research Abuse, Diversion andAddiction-Related Surveil-
lance (RADARS) System Poison Centers Program in the US that showed
a linear increase in NMPO in adults aged 20 to 59 years between 2006
and 2013 (West, Severtson, Green, & Dart, 2015). Declines in NMPO
use in the same period (2003–2014) have been seen among adolescents
in the NSDUH after the year 2008 (Vaughn, Nelson, Salas-Wright, Qian,
& Schootman, 2016), and in other datasets such as the Monitoring the
Future (MTF), where declines after the same year (2008) in prescription
opioid use (like Vicodin® and Oxycontin®) among12th graders, college
students and young adults were reported (Miech, Johnston, O'Malley,
Bachman, Schulenberg, & Patrick, 2015). Similarly, McCabe et al. report-
ed declines in NMPO use among U.S. college students in the Midwest
from 2003 to 2013 (McCabe, West, Teter, & Boyd, 2014). Our study
not only expands the analyses of this trend by investigating prescription
opioid use disorder secondary to use in across a 13-year span, but adds
two important findings: 1) an increasing trend of this disorder found
among young adult users aged 18–35; and 2) a parallel increasing
trend in heroin use among NMPO users in the same age range.
Previous research in U.S. population 12 years and older, using
NSDUH data, supports the relationship between prescription opioid
and heroin use; an increase in heroin use was found among those
reporting NMPO use between 2002–2005 and 2008–2011 (Martins,
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%
Fig. 4. Total percentage change from 2002 to 2014 in heroin use prevalence among NMPO
users, in the U.S. household population, by age groups.separate analysis showed that 3.6% of NMPOusers initiate heroinwithin
five years of NMPO initiation and 4.2%of NMPOusers alsousedheroin in
the past-year (Compton et al., 2016). Our study is in accordance with
past research (Blanco et al., 2007), as we found a worrisome increasing
trend in heroin use amongNMPO users, in particular in 18–34 year olds.
Although our study does not assess underlying causes, the increasing
trend in prescription opioid use disorder observed in young adults
might be at least partially explained by historical factors described else-
where in the literature, such as: a shift inmedical practice of prescribing
opioids from end-of-life pain and cancer to chronic non-cancer pain,
particularly in young adults (Franklin et al., 2015); an increased rate of
opioid prescription by physicians due to a higher sensitivity to patient's
pain (CDC, 2012); the endorsement of pain as a “fifth vital sign” by the
Joint Commission with a controverted pain metric (Franklin et al.,
2015); an increased distribution of opioids by the pharmaceutical in-
dustry and creation of an opioid rich environment (Rintoul & Dobbin,
2014); state lobbying by pain advocates for prescription opioids use;
physician sensitivity to pain exploitation by opioid users; as well as
“doctor shopping” by patients (Ballantyne & Kolodny, 2015; CDC,
2012; Shepherd, 2014) and overprescribing (Compton et al., 2016),
which leaves excess medications available for misuse or redistribution
via nonmedical sanctioned venues. In addition, Friedman suggests that
positive media attention, which fosters an image that prescription
drug use is a routine aspect of everyday life, together with an increase
in the pharmaceutical industry expenditures in direct-to-consumer ad-
vertising, has led to growing confidence in the safety of using prescrip-
tion drugs nonmedically (i.e., ‘normalization” of nonmedical use of
these drugs) (Friedman, 2006). This could be worrisome given normal-
ization of attitudes and behaviors upon exposure to mass media, espe-
cially among impressionable youths (Montgomery, 2000).
Our study is not void of limitations including the fact that weights
from the 2002–2010NSDUHwere calculated using the 2000 U.S. census
data,while the 2011–2014weightswere based on 2010 census data. Al-
though this might have slightly affected the comparability of estimates
across years, evidence shows that the impact of this change on esti-
mates are not substantial (SAMHSA, 2012a). Moreover, as in most
large-scale epidemiologic surveys, information is based on self-report,
and there might be recall bias in reporting both drug use and other sen-
sitive behaviors (Morral et al., 2003), keeping in mind that our study
was limited to use, and use disorder in the preceding year at each
year. Still, respondents might under-report prescription opioid use dis-
order symptoms and their use of heroin which is a drug that has more
stigma associated with it. Also, data to distinguish whether these
NMPO users first started using these drugs when legitimately pre-
scribed (e.g., pain relief) or when obtained illegally (i.e., to get high)
are still unavailable in the NSDUH. Similarly, with the data used in this
paper we cannot make real inferences on whether NMPO use preceded
heroin use onset due to the cross-sectional nature of the annual NSDUH
and the limited availability ondata on age of onset (available only for re-
spondents up to age 21). However, data on age offirst use for heroin and
NMPO is available in the NSDUH data sets. We ran post-hoc analyses
among those that endorsed using NMPO and found that, among the
three age groups, the vast majority had started using heroin after
starting NMPO use. Specifically, 52.98% of those 12–17 years old,
78.51% of those 18–24 years old, and 69.16% of those 25–34 years old
had higher age of onset for heroin use than for NMPO use (see Supple-
mental Table 3).
5. Conclusion
In conclusion, between 2002 and 2014, prescription opioid-related
use disorders secondary to nonmedical use and heroin use among
NMPO users increased among emerging and young adults. Although
our descriptive analyses do not address the potential causes in the rise
of these trends, it seeks to present the evidence in order to raise aware-
ness and urgency to address these rising and problematic trends among
240 S.S. Martins et al. / Addictive Behaviors 65 (2017) 236–241youth. There is some evidence that increases in prescription opioid use
disorder secondary to NMPO usemight be rooted in health policy, med-
ical practice, pharmaceutical industry interests and patient behavior
(Belcher et al., 2014). While pain management is an important feature
in the medical conversation and practice when patients are prescribed
prescription opioids (Dowell, Haegerich, & Chou, 2016), it is imperative
that the general public, particularly youth, are informed about the relat-
ed harms and disorders that can occur when prescription opioids are
used without regular medical supervision.
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